The global market for GLP-1 Weight Loss Injection was valued at US$ 956 million in the year 2023 and is projected to reach a revised size of US$ 2029 million by 2030, growing at a CAGR of 11.2% during the forecast period.
GLP-1 (glucagon-like peptide-1) weight loss injection is a weight loss drug developed based on GLP-1 or its analogs. It is injected to simulate or enhance the physiological effects of GLP-1 to help people lose weight. GLP-1 (glucagon-like peptide-1) weight loss injection can help people suppress appetite, slow down gastric emptying, promote fat metabolism, etc. At present, there are many GLP-1 weight loss drugs on the market, such as liraglutide, benaglutide, semaglutide and Tirzepatide.
North American market for GLP-1 Weight Loss Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Weight Loss Injection is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Weight Loss Injection include Novo Nordisk, Eli Lilly, Huadong Medicine, Borui Pharmaceuticals, Hengrui Medicine, Innovent Biologics, Shanghai Benemae Biopharmaceuticals Co., Ltd., Gan & Lee Pharmaceuticals, CSPC Pharmaceutical Group, Hansoh Pharmaceuticals, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for GLP-1 Weight Loss Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Weight Loss Injection.
The GLP-1 Weight Loss Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global GLP-1 Weight Loss Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Weight Loss Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Novo Nordisk
Eli Lilly
Huadong Medicine
Borui Pharmaceuticals
Hengrui Medicine
Innovent Biologics
Shanghai Benemae Biopharmaceuticals Co., Ltd.
Gan & Lee Pharmaceuticals
CSPC Pharmaceutical Group
Hansoh Pharmaceuticals
Wanbang Biopharma
Sihuan Pharmaceuticals
Imeik
by Type
Liraglutide
Semaglutide
Tirzepatide
Benaglutide
Others
by Application
Hospital
Clinic
Others
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Weight Loss Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Weight Loss Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 GLP-1 Weight Loss Injection 麻豆原创 Overview
1.1 Product Definition
1.2 GLP-1 Weight Loss Injection by Type
1.2.1 Global GLP-1 Weight Loss Injection 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Liraglutide
1.2.3 Semaglutide
1.2.4 Tirzepatide
1.2.5 Benaglutide
1.2.6 Others
1.3 GLP-1 Weight Loss Injection by Application
1.3.1 Global GLP-1 Weight Loss Injection 麻豆原创 Value by Application (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global GLP-1 Weight Loss Injection 麻豆原创 Size Estimates and Forecasts
1.4.1 Global GLP-1 Weight Loss Injection Revenue 2019-2030
1.4.2 Global GLP-1 Weight Loss Injection Sales 2019-2030
1.4.3 Global GLP-1 Weight Loss Injection 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 GLP-1 Weight Loss Injection 麻豆原创 Competition by Manufacturers
2.1 Global GLP-1 Weight Loss Injection Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global GLP-1 Weight Loss Injection Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global GLP-1 Weight Loss Injection Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of GLP-1 Weight Loss Injection, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Weight Loss Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Weight Loss Injection, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Weight Loss Injection, Date of Enter into This Industry
2.8 Global GLP-1 Weight Loss Injection 麻豆原创 Competitive Situation and Trends
2.8.1 Global GLP-1 Weight Loss Injection 麻豆原创 Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Weight Loss Injection Players 麻豆原创 Share by Revenue
2.8.3 Global GLP-1 Weight Loss Injection 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Weight Loss Injection 麻豆原创 Scenario by Region
3.1 Global GLP-1 Weight Loss Injection 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global GLP-1 Weight Loss Injection Sales by Region: 2019-2030
3.2.1 Global GLP-1 Weight Loss Injection Sales by Region: 2019-2024
3.2.2 Global GLP-1 Weight Loss Injection Sales by Region: 2025-2030
3.3 Global GLP-1 Weight Loss Injection Revenue by Region: 2019-2030
3.3.1 Global GLP-1 Weight Loss Injection Revenue by Region: 2019-2024
3.3.2 Global GLP-1 Weight Loss Injection Revenue by Region: 2025-2030
3.4 North America GLP-1 Weight Loss Injection 麻豆原创 Facts & Figures by Country
3.4.1 North America GLP-1 Weight Loss Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America GLP-1 Weight Loss Injection Sales by Country (2019-2030)
3.4.3 North America GLP-1 Weight Loss Injection Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Weight Loss Injection 麻豆原创 Facts & Figures by Country
3.5.1 Europe GLP-1 Weight Loss Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe GLP-1 Weight Loss Injection Sales by Country (2019-2030)
3.5.3 Europe GLP-1 Weight Loss Injection Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Weight Loss Injection 麻豆原创 Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Weight Loss Injection 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific GLP-1 Weight Loss Injection Sales by Region (2019-2030)
3.6.3 Asia Pacific GLP-1 Weight Loss Injection Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Weight Loss Injection 麻豆原创 Facts & Figures by Country
3.7.1 Latin America GLP-1 Weight Loss Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America GLP-1 Weight Loss Injection Sales by Country (2019-2030)
3.7.3 Latin America GLP-1 Weight Loss Injection Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Weight Loss Injection 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Weight Loss Injection 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa GLP-1 Weight Loss Injection Sales by Country (2019-2030)
3.8.3 Middle East and Africa GLP-1 Weight Loss Injection Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Weight Loss Injection Sales by Type (2019-2030)
4.1.1 Global GLP-1 Weight Loss Injection Sales by Type (2019-2024)
4.1.2 Global GLP-1 Weight Loss Injection Sales by Type (2025-2030)
4.1.3 Global GLP-1 Weight Loss Injection Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global GLP-1 Weight Loss Injection Revenue by Type (2019-2030)
4.2.1 Global GLP-1 Weight Loss Injection Revenue by Type (2019-2024)
4.2.2 Global GLP-1 Weight Loss Injection Revenue by Type (2025-2030)
4.2.3 Global GLP-1 Weight Loss Injection Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global GLP-1 Weight Loss Injection Price by Type (2019-2030)
5 Segment by Application
5.1 Global GLP-1 Weight Loss Injection Sales by Application (2019-2030)
5.1.1 Global GLP-1 Weight Loss Injection Sales by Application (2019-2024)
5.1.2 Global GLP-1 Weight Loss Injection Sales by Application (2025-2030)
5.1.3 Global GLP-1 Weight Loss Injection Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global GLP-1 Weight Loss Injection Revenue by Application (2019-2030)
5.2.1 Global GLP-1 Weight Loss Injection Revenue by Application (2019-2024)
5.2.2 Global GLP-1 Weight Loss Injection Revenue by Application (2025-2030)
5.2.3 Global GLP-1 Weight Loss Injection Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global GLP-1 Weight Loss Injection Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk GLP-1 Weight Loss Injection Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly GLP-1 Weight Loss Injection Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Huadong Medicine
6.3.1 Huadong Medicine Company Information
6.3.2 Huadong Medicine Description and Business Overview
6.3.3 Huadong Medicine GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Huadong Medicine GLP-1 Weight Loss Injection Product Portfolio
6.3.5 Huadong Medicine Recent Developments/Updates
6.4 Borui Pharmaceuticals
6.4.1 Borui Pharmaceuticals Company Information
6.4.2 Borui Pharmaceuticals Description and Business Overview
6.4.3 Borui Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Borui Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
6.4.5 Borui Pharmaceuticals Recent Developments/Updates
6.5 Hengrui Medicine
6.5.1 Hengrui Medicine Company Information
6.5.2 Hengrui Medicine Description and Business Overview
6.5.3 Hengrui Medicine GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hengrui Medicine GLP-1 Weight Loss Injection Product Portfolio
6.5.5 Hengrui Medicine Recent Developments/Updates
6.6 Innovent Biologics
6.6.1 Innovent Biologics Company Information
6.6.2 Innovent Biologics Description and Business Overview
6.6.3 Innovent Biologics GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Innovent Biologics GLP-1 Weight Loss Injection Product Portfolio
6.6.5 Innovent Biologics Recent Developments/Updates
6.7 Shanghai Benemae Biopharmaceuticals Co., Ltd.
6.7.1 Shanghai Benemae Biopharmaceuticals Co., Ltd. Company Information
6.7.2 Shanghai Benemae Biopharmaceuticals Co., Ltd. Description and Business Overview
6.7.3 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Shanghai Benemae Biopharmaceuticals Co., Ltd. GLP-1 Weight Loss Injection Product Portfolio
6.7.5 Shanghai Benemae Biopharmaceuticals Co., Ltd. Recent Developments/Updates
6.8 Gan & Lee Pharmaceuticals
6.8.1 Gan & Lee Pharmaceuticals Company Information
6.8.2 Gan & Lee Pharmaceuticals Description and Business Overview
6.8.3 Gan & Lee Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Gan & Lee Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
6.8.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.9 CSPC Pharmaceutical Group
6.9.1 CSPC Pharmaceutical Group Company Information
6.9.2 CSPC Pharmaceutical Group Description and Business Overview
6.9.3 CSPC Pharmaceutical Group GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CSPC Pharmaceutical Group GLP-1 Weight Loss Injection Product Portfolio
6.9.5 CSPC Pharmaceutical Group Recent Developments/Updates
6.10 Hansoh Pharmaceuticals
6.10.1 Hansoh Pharmaceuticals Company Information
6.10.2 Hansoh Pharmaceuticals Description and Business Overview
6.10.3 Hansoh Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Hansoh Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
6.10.5 Hansoh Pharmaceuticals Recent Developments/Updates
6.11 Wanbang Biopharma
6.11.1 Wanbang Biopharma Company Information
6.11.2 Wanbang Biopharma Description and Business Overview
6.11.3 Wanbang Biopharma GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Wanbang Biopharma GLP-1 Weight Loss Injection Product Portfolio
6.11.5 Wanbang Biopharma Recent Developments/Updates
6.12 Sihuan Pharmaceuticals
6.12.1 Sihuan Pharmaceuticals Company Information
6.12.2 Sihuan Pharmaceuticals Description and Business Overview
6.12.3 Sihuan Pharmaceuticals GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Sihuan Pharmaceuticals GLP-1 Weight Loss Injection Product Portfolio
6.12.5 Sihuan Pharmaceuticals Recent Developments/Updates
6.13 Imeik
6.13.1 Imeik Company Information
6.13.2 Imeik Description and Business Overview
6.13.3 Imeik GLP-1 Weight Loss Injection Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Imeik GLP-1 Weight Loss Injection Product Portfolio
6.13.5 Imeik Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Weight Loss Injection Industry Chain Analysis
7.2 GLP-1 Weight Loss Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Weight Loss Injection Production Mode & Process
7.4 GLP-1 Weight Loss Injection Sales and 麻豆原创ing
7.4.1 GLP-1 Weight Loss Injection Sales Channels
7.4.2 GLP-1 Weight Loss Injection Distributors
7.5 GLP-1 Weight Loss Injection Customers
8 GLP-1 Weight Loss Injection 麻豆原创 Dynamics
8.1 GLP-1 Weight Loss Injection Industry Trends
8.2 GLP-1 Weight Loss Injection 麻豆原创 Drivers
8.3 GLP-1 Weight Loss Injection 麻豆原创 Challenges
8.4 GLP-1 Weight Loss Injection 麻豆原创 Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Novo Nordisk
Eli Lilly
Huadong Medicine
Borui Pharmaceuticals
Hengrui Medicine
Innovent Biologics
Shanghai Benemae Biopharmaceuticals Co., Ltd.
Gan & Lee Pharmaceuticals
CSPC Pharmaceutical Group
Hansoh Pharmaceuticals
Wanbang Biopharma
Sihuan Pharmaceuticals
Imeik
听
听
*If Applicable.